HomeCompareSRBCF vs ABBV

SRBCF vs ABBV: Dividend Comparison 2026

SRBCF yields 39215.69% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SRBCF wins by $4.252735580217355e+22M in total portfolio value
10 years
SRBCF
SRBCF
● Live price
39215.69%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.252735580217355e+22M
Annual income
$42,315,093,309,418,040,000,000,000,000.00
Full SRBCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SRBCF vs ABBV

📍 SRBCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSRBCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SRBCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SRBCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SRBCF
Annual income on $10K today (after 15% tax)
$3,333,333.33/yr
After 10yr DRIP, annual income (after tax)
$35,967,829,313,005,333,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, SRBCF beats the other by $35,967,829,313,005,333,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SRBCF + ABBV for your $10,000?

SRBCF: 50%ABBV: 50%
100% ABBV50/50100% SRBCF
Portfolio after 10yr
$2.1263677901086776e+22M
Annual income
$21,157,546,654,709,020,000,000,000,000.00/yr
Blended yield
99.50%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SRBCF
No analyst data
Altman Z
-90.9
Piotroski
2/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SRBCF buys
0
ABBV buys
0
No recent congressional trades found for SRBCF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSRBCFABBV
Forward yield39215.69%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.252735580217355e+22M$102.3K
Annual income after 10y$42,315,093,309,418,040,000,000,000,000.00$24,771.77
Total dividends collected$4.251340866571809e+22M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SRBCF vs ABBV ($10,000, DRIP)

YearSRBCF PortfolioSRBCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$3,932,269$3,921,568.63$11,550$430.00+$3.92MSRBCF
2$1,445,390,825$1,441,183,297.58$13,472$627.96+$1445.38MSRBCF
3$496,629,048,205$495,082,480,022.34$15,906$926.08+$496629.03MSRBCF
4$159,510,701,964,776$158,979,308,883,196.16$19,071$1,382.55+$159510701.95MSRBCF
5$47,892,225,784,148,210$47,721,549,333,045,900.00$23,302$2,095.81+$47892225784.12MSRBCF
6$13,442,027,069,357,296,000$13,390,782,387,768,257,000.00$29,150$3,237.93+$13442027069357.27MSRBCF
7$3,526,928,149,355,307,700,000$3,512,545,180,391,095,400,000.00$37,536$5,121.41+$3526928149355307.50MSRBCF
8$865,104,634,553,737,800,000,000$861,330,821,433,927,700,000,000.00$50,079$8,338.38+$865104634553737856.00MSRBCF
9$198,376,161,453,751,100,000,000,000$197,450,499,494,778,630,000,000,000.00$69,753$14,065.80+$198376161453751107584.00MSRBCF
10$42,527,355,802,173,560,000,000,000,000$42,315,093,309,418,040,000,000,000,000.00$102,337$24,771.77+$4.252735580217355e+22MSRBCF

SRBCF vs ABBV: Complete Analysis 2026

SRBCFStock

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects include the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. Sirona Biochem Corp. has a research collaboration agreement with the International Centre for Genetic Engineering and Biotechnology (ICGEB) to develop antiviral library of compounds. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Full SRBCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SRBCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SRBCF vs SCHDSRBCF vs JEPISRBCF vs OSRBCF vs KOSRBCF vs MAINSRBCF vs JNJSRBCF vs MRKSRBCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.